致病性大肠埃希菌耐药性研究进展

doi:10.20047/j.issn1673-7210.2022.25.12

Abstract
Figure/Table
References (34)
Related Citation (4)

Download: PDF (524 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Pathogenic Escherichia coli can infect important tissues and organs through various infection routes in clinical practice. The irregular use of antibiotics leads to the accumulation and spread of bacterial resistance. Recent studies have shown that antibiotic resistance of pathogenic Escherichia coli is becoming increasingly severe. This article discusses the current status of drug resistance of common pathogenic Escherichia coli in clinical practice, and summarizes the drug resistance mechanisms of pathogenic Escherichia coli from the aspects of mobile genetic elements, target mutation and modification, and inactivated enzymes, explore the genetic engineering or molecular biology, Chinese medicine and some other novel non-antibiotic therapy methods, in order to provide reference information for alleviating the drug resistance of pathogenic Escherichia coli.

Key words： Pathogenic Escherichia coli Current situation of drug resistance Resistance mechanisms Treatment methods

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	REN Chenyin1 FU Yixiu2▲

Cite this article:

REN Chenyin1 FU Yixiu2▲. Research progress on antibiotic resistance of pathogenic Escherichia coli[J]. 中国医药导报, 2022, 19(25): 55-58.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.25.12 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I25/55

[1] Braz VS，Melchior K，Moreira CG. Escherichia coli as a Multifaceted Pathogenic and Versatile Bacterium [J]. Front Cell Infect Microbiol，2020，10：548492.
[2] Sora VM，Meroni G，Martino PA，et al. Extraintestinal Path-ogenic Escherichia coli：Virulence Factors and Antibiotic Resistance [J]. Pathogens，2021，10（11）：1355.
[3] Denamur E，Clermont O，Bonacorsi S，et al. The population genetics of pathogenic Escherichia coli [J]. Nat Rev Microbiol，2021，19（1）：37-54.
[4] Duan YT，Gao HH，Zheng LY，et al. Antibiotic Resistance and Virulence of Extraintestinal Pathogenic Escherichia coli （ExPEC） Vary According to Molecular Types [J]. Front Microbiol，2020，11：598305.
[5] Raeispour M，Ranjbar R. Antibiotic resistance，virulence factors and genotyping of Uropathogenic Escherichia coli strains [J]. Antimicrob Resist Infect Control，2018，7：118.
[6] Shahbazi S，Asadi Karam MR，Habibi M，et al. Distribution of extended-spectrum β-lactam，quinolone and carbapenem resistance genes，and genetic diversity among uropathogenic Escherichia coli isolates in Tehran，Iran [J]. J Glob Antimicrob Resist，2018，14：118-125.
[7] Sun DH，Lv DF，Mi ZH，et al. Investigation of antibiotic resistance determinants and virulence factors of uropa-thogenic Escherichia coli [J]. J Antibiot （Tokyo），2020，73（5）：314-319.
[8] Begier E，Rosenthal NA，Gurtman A，et al. Epidemiology of Invasive Escherichia coli Infection and Antibiotic Resistance Status Among Patients Treated in US Hospitals：2009-2016 [J]. Clin Infect Dis，2021，73（4）：565-574.
[9] Rubab M，Oh DH. Virulence Characteristics and Antibiotic Resistance Profiles of Shiga Toxin-Producing Escherichia coli Isolates from Diverse Sources [J]. Antibiotics （Basel），2020，9（9）：587.
[10] Javadi K，Mohebi S，Motamedifar M，et al. Characterization and antibiotic resistance pattern of diffusely adherent Escherichia coli （DAEC），isolated from paediatric diarrhoea in Shiraz，southern Iran [J]. New Microbes New Infect，2020，38：100780.
[11] Li QY，Zhao P，Li LL，et al. Engineering a CRISPR Interference System To Repress a Class 1 Integron in Escherichia coli [J]. Antimicrob Agents Chemother，2020， 64（3）：e01789-19.
[12] Zhang SQ，Abbas M，Rehman MU，et al. Dissemination of antibiotic resistance genes （ARGs） via integrons in Escherichia coli：A risk to human health [J]. Environ Pollut，2020，266（Pt 2）：115260.
[13] Asadi Karam MR，Habibi M，Bouzari S. Urinary tract infection：Pathogenicity，antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli [J]. Mol Immunol，2019，108：56-67.
[14] Halaji M，Feizi A，Mirzaei A，et al. The Global Prevalence of Class 1 Integron and Associated Antibiotic Resistance in Escherichia coli from Patients with Urinary Tract Infections，a Systematic Review and Meta-Analysis [J]. Microb Drug Resist，2020，26（10）：1208-1218.
[15] 杨超，俸婷婷，刘雄利，等.细菌多重耐药机制及其检测方法研究新进展[J].中国病原生物学杂志，2015，10（11）：1047-1050.
[16] Shalaby MW，Dokla EME，Serya RAT，et al. Penicillin binding protein 2a：An overview and a medicinal chemistry perspective [J]. Eur J Med Chem，2020，199：112312.
[17] Olsen I. New promising β-lactamase inhibitors for clinical use [J]. Eur J Clin Microbiol Infect Dis，2015，34（7）：1303-1308.
[18] Hobbs EC，Yin XF，Paul BJ，et al. Conserved small protein associates with the multidrug efflux pump AcrB and differentially affects antibiotic resistance [J]. Proc Natl Acad Sci U S A，2012，109（41）：16696-16701.
[19] Grande R，Puca V，Muraro R. Antibiotic resistance and bacterial biofilm [J]. Expert Opin Ther Pat，2020，30（12）：897-900.
[20] Zhao F，Yang HX，Bi DZ，et al. A systematic review and meta-analysis of antibiotic resistance patterns，and the correlation between biofilm formation with virulence factors in uropathogenic E. coli isolated from urinary tract infections [J]. Microb Pathog，2020，144：104196.
[21] 国家卫生计生委办公厅.国家卫生计生委印发抗菌药物临床应用指导原则（2015版）[EB/OL][2015-7-24]. http：//www.nhfpc.gov.cn/yzygj/s3593/201508/c18e1014d e6c45ed9f6f9d592b43db42.shtml.
[22] Wan F，Draz MS，Gu M，et al. Novel Strategy to Combat Antibiotic Resistance：A Sight into the Combination of CRISPR/Cas9 and Nanoparticles [J]. Pharmaceutics，2021， 13（3）：352.
[23] Kim JS，Cho DH，Park M，et al. CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases [J]. J Microbiol Biotechnol，2016，26（2）：394-401.
[24] Hao M，He YZ，Zhang HF，et al. CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant Enterobacteriaceae [J]. Antimicrob Agents Chemother，2020，64（9）：e00843-20.
[25] 张炳亮，董发明，王文文，等.中药与抗菌药物联用对猪源大肠杆菌耐药性的抑制作用[J].中国畜牧兽医，2018， 45（9）：2628-2636.
[26] 李海华，郭蔚冰，陈志强，等.45味中药对多重耐药大肠杆菌的抑菌效果[J].中国现代中药，2019，21（6）：791-796.
[27] 宁官保，牛艺儒，张鼎，等.鸡源大肠杆菌耐药性分析及中药对大肠杆菌耐药性消除作用的研究[J].畜牧兽医学报，2015，46（6）：1018-1025.
[28] 衡雪源，左志文，朱德全，等.加味黄连解毒汤逆转大肠埃希菌耐药性的试验研究[J].中兽医医药杂志，2020， 39（3）：13-16.
[29] 贾丽阳，邓冬，孙丽华，等.中药治疗耐药菌感染作用机制研究进展[J].中国实验方剂学杂志，2020，26（16）：228-234.
[30] 黄璨，陈枫，彭继超，等.川贝母对大肠埃希菌生物被膜的影响研究[J].中华医院感染学杂志，2017，27（22）：5049-5052.
[31] North OI，Brown ED. Phage-antibiotic combinations：a promising approach to constrain resistance evolution in bacteria [J]. Ann N Y Acad Sci，2021，1496（1）：23-34.
[32] Moradpour Z，Yousefi N，Sadeghi D，et al. Synergistic bactericidal activity of a naturally isolated phage and ampicillin against urinary tract infecting Escherichia coli O157 [J]. Iran J Basic Med Sci，2020，23（2）：257-263.
[33] Feng Y，Coradi Tonon C，Ashraf S，et al. Photodynamic and antibiotic therapy in combination against bacterial infections：efficacy，determinants，mechanisms，and future perspectives [J]. Adv Drug Deliv Rev，2021，177：113941.
[34] Feng Y，Palanisami A，Ashraf S，et al. Photodynamic inactivation of bacterial carbapenemases restores bacterial carbapenem susceptibility and enhances carbapenem antibiotic effectiveness [J]. Photodiagnosis Photodyn Ther，2020，30：101693.